Importantly, these differences were not due to differences in IAV infection/replication efficiency caused by the pre-infecting paramyxovirus, as determined by co-infection immunostaining (Fig 5A), assessment of IAV protein levels (Fig 5B), or assessment of changes in global SUMO2/3-conjugated protein levels (Fig 5B). The gene discussed is SUMO2; the disease is coinfection.